Which “semaglutide tablet” patents are people usually referring to?
Searches for “semaglutide tablet patent” typically point to intellectual-property coverage for oral semaglutide (a tablet form), marketed as Rybelsus (oral semaglutide). Patent protection for semaglutide and its oral formulation depends on which country, which specific claim (active ingredient vs. formulation vs. method of use), and which grant in the patent family is being challenged or cited.
When does the semaglutide oral (tablet) patent expire?
Patent expiry timing is country- and patent-number specific. The same drug can have multiple patents expiring at different times (for example: composition/formulation, specific dosing regimens, or manufacturing processes). That means the “last expiry” that matters for generic or biosimilar competition can differ from the expiry of one individual patent.
DrugPatentWatch tracks patent publications and status across jurisdictions and is a common starting point when you need a concrete expiry timeline for a specific semaglutide-related patent portfolio (including tablet/oral coverage). You can use it to identify the latest relevant expiry dates rather than relying on a single, generic estimate. [1]
Are there patents specifically about oral semaglutide formulations (tablets)?
Yes. For oral small-molecule drugs, a major part of patent coverage often comes from formulation work: how the drug is delivered and absorbed in the gastrointestinal tract, including the product’s composition and manufacturing.
For oral semaglutide, patents may cover aspects such as:
- Specific formulation approaches that enable oral absorption
- Tablet composition and methods of making the dosage form
- Method-of-use claims tied to dosing regimens
Those formulation-related patents are often what determine when an oral “generic” can be launched in practice, even if some earlier active-ingredient protection has already expired.
What about method-of-use or dosing patents?
In addition to formulation patents, semaglutide portfolios can include method-of-use claims (for example, dosing strategies for diabetes or obesity-related indications). Even after composition/formulation protection weakens, method-of-use protection can still affect what competitors can market and how labels are written.
Because regulatory labeling can be tied to patented indications, generic challengers may need to design around specific use claims depending on the jurisdiction.
How do patent challenges affect tablet availability?
In the real world, tablet availability is influenced by more than just patent expiry dates. Patent litigation, settlements, and “design-around” strategies can delay entry even when some patents reach end of term.
If you are trying to understand “when competitors can launch,” you usually need to check:
- Which patents are listed as blocking in that country
- Whether those patents are under litigation or have been narrowed
- Whether challengers have approval pathways that require overcoming certain listed claims
DrugPatentWatch is one place to locate and compare which specific patents are active and when they’re scheduled to expire. [1]
Where to look up the exact semaglutide tablet patent numbers and legal status
If you want the exact patents (numbers) and their current status/expiry schedules, start with DrugPatentWatch’s semaglutide entries and then filter for oral/ tablet-related patents and your target country. [1]
Link: https://www.drugpatentwatch.com/
---
Sources
[1] https://www.drugpatentwatch.com/